VERA Vera Therapeutics, Inc. - 8-K

Item 8.01 Other Events.

On June 2, 2026, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing that the Company has aligned with the U.S. Food and Drug Administration on a revised, earlier ORIGIN 3 eGFR analysis plan to support the potential full approval of atacicept in adults with IgA Nephropathy. The eGFR results are now expected in the third quarter of 2026. Pending these results, the Company plans to submit a supplemental Biologics License Application for full approval of atacicept in the fourth quarter of 2026.

Forward Looking Statements

Statements contained in this Current Report on Form 8-K regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements about the Company’s expectations regarding the approval of atacicept by the U.S. Food and Drug Administration, the timing of eGFR results, and the submission by the Company of a supplemental Biologics License Application for full approval of atacicept as well as the timing of such submission. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “expects,” “plans,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with the Company’s business in general, the impact of macroeconomic and geopolitical events and the other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.